Which trial do we need? Long-acting glycopeptides versus oral antibiotics for infective endocarditis in patients with substance use disorder

Alysse G. Wurcel; Daniel C. DeSimone; Laura Marks; Larry M. Baddour; Parham Sendi

doi:10.1016/j.cmi.2023.04.005

Which trial do we need? Long-acting glycopeptides versus oral antibiotics for infective endocarditis in patients with substance use disorder

Alysse G. Wurcel, Daniel C. DeSimone, Laura Marks, Larry M. Baddour, Parham Sendi

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	952-954
Number of pages	3
Journal	Clinical Microbiology and Infection
Volume	29
Issue number	8
DOIs	https://doi.org/10.1016/j.cmi.2023.04.005
State	Published - Aug 2023

Keywords

Endocarditis
Oral antibiotics
Oritavancin
People who inject drugs

Access to Document

10.1016/j.cmi.2023.04.005

Cite this

@article{afbfaf87e1fe4dccb2f32d205994a739,

title = "Which trial do we need? Long-acting glycopeptides versus oral antibiotics for infective endocarditis in patients with substance use disorder",

keywords = "Endocarditis, Oral antibiotics, Oritavancin, People who inject drugs",

author = "Wurcel, {Alysse G.} and DeSimone, {Daniel C.} and Laura Marks and Baddour, {Larry M.} and Parham Sendi",

note = "Funding Information: LMB reports authorship duties from UpToDate, Inc., and consulting fees for Boston Scientific, Roivant Sciences, and Botanix Pharmaceuticals. `The other authors declare that they have no conflicts of interest.",

year = "2023",

month = aug,

doi = "10.1016/j.cmi.2023.04.005",

language = "English",

volume = "29",

pages = "952--954",

journal = "Clinical Microbiology and Infection",

issn = "1198-743X",

number = "8",

}

TY - JOUR

T1 - Which trial do we need? Long-acting glycopeptides versus oral antibiotics for infective endocarditis in patients with substance use disorder

AU - Wurcel, Alysse G.

AU - DeSimone, Daniel C.

AU - Marks, Laura

AU - Baddour, Larry M.

AU - Sendi, Parham

N1 - Funding Information: LMB reports authorship duties from UpToDate, Inc., and consulting fees for Boston Scientific, Roivant Sciences, and Botanix Pharmaceuticals. `The other authors declare that they have no conflicts of interest.

PY - 2023/8

Y1 - 2023/8

KW - Endocarditis

KW - Oral antibiotics

KW - Oritavancin

KW - People who inject drugs

UR - http://www.scopus.com/inward/record.url?scp=85154589876&partnerID=8YFLogxK

U2 - 10.1016/j.cmi.2023.04.005

DO - 10.1016/j.cmi.2023.04.005

M3 - Comment/debate

C2 - 37044275

AN - SCOPUS:85154589876

SN - 1198-743X

VL - 29

SP - 952

EP - 954

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

IS - 8

ER -

Which trial do we need? Long-acting glycopeptides versus oral antibiotics for infective endocarditis in patients with substance use disorder

Keywords

Access to Document

Other files and links

Cite this